Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
L Kujtan, J Subramanian - Expert Review of Anticancer Therapy, 2019 - Taylor & Francis
Introduction: Epidermal growth factor receptor (EGFR) mutations are well-described drivers
of non-small cell lung cancer (NSCLC) and EGFR tyrosine kinase inhibitors (TKIs) have …
of non-small cell lung cancer (NSCLC) and EGFR tyrosine kinase inhibitors (TKIs) have …
Generations of epidermal growth factor receptor tyrosine kinase inhibitors: perils and progress
EH Castellanos, L Horn - Current treatment options in oncology, 2015 - Springer
Opinion statement Epidermal growth factor receptor (EGFR) mutations have been detected
in approximately 10% of North American patients diagnosed with non-small cell lung cancer …
in approximately 10% of North American patients diagnosed with non-small cell lung cancer …
[PDF][PDF] Epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
F Ogunleye, M Ibrahim, M Stender… - Am J …, 2015 - gotoper-com.s3.amazonaws.com
Epidermal growth factor receptor (EGFR) mutations act as oncogenic drivers in the cellular
signal transduction pathway and induce downstream activation of several key cellular …
signal transduction pathway and induce downstream activation of several key cellular …
Overcoming resistance to EGFR inhibitors in NSCLC
P Maione, PC Sacco, F Casaluce… - Reviews on Recent …, 2016 - ingentaconnect.com
Background: The clarification of several molecular pathways underlying the tumorigenesis
has led to the development of several targeted drugs that have substantially improved the …
has led to the development of several targeted drugs that have substantially improved the …
EGFR tyrosine kinase inhibitors in lung cancer: an evolving story
LV Sequist, TJ Lynch - Annu. Rev. Med., 2008 - annualreviews.org
Drugs that target the epidermal growth factor receptor (EGFR) have had a major impact on
the treatment of non–small cell lung cancer (NSCLC). The use of these drugs has also …
the treatment of non–small cell lung cancer (NSCLC). The use of these drugs has also …
[HTML][HTML] Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation …
M Roengvoraphoj, GJ Tsongalis, KH Dragnev… - Cancer treatment …, 2013 - Elsevier
Activation of the epidermal growth factor receptor (EGFR) pathway has been implicated in
tumorigenesis in non-small cell lung cancer (NSCLC), the most common type of lung cancer …
tumorigenesis in non-small cell lung cancer (NSCLC), the most common type of lung cancer …
Epidermal Growth Factor Receptor targeting in non-small cell lung cancer: revisiting different strategies against the same target
Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed
the paradigm of treatment in non-small cell lung cancer (NSCLC). The molecular biology …
the paradigm of treatment in non-small cell lung cancer (NSCLC). The molecular biology …
Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations
PA Jänne - Seminars in oncology, 2005 - Elsevier
The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic
target for patients with non–small cell lung cancer (NSCLC). However, despite its almost …
target for patients with non–small cell lung cancer (NSCLC). However, despite its almost …
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
R Pirker - Current opinion in oncology, 2016 - journals.lww.com
Third-generation epidermal growth factor receptor tyrosine k... : Current Opinion in Oncology
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced …
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced …
[HTML][HTML] Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
A Martinez-Marti, A Navarro, E Felip - Translational Lung Cancer …, 2019 - ncbi.nlm.nih.gov
The epidermal growth factor receptor (EGFR) oncogene was positioned as an attractive
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …